- Home
- MNPR vs KNOP Comparison
MNPR vs KNOP Comparison
Compare MNPR & KNOP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNPR
- KNOP
- Stock Information
- Founded
- MNPR 2014
- KNOP 2013
- Country
- MNPR United States
- KNOP United Kingdom
- Employees
- MNPR N/A
- KNOP N/A
- Industry
- MNPR Biotechnology: Pharmaceutical Preparations
- KNOP Marine Transportation
- Sector
- MNPR Health Care
- KNOP Consumer Discretionary
- Exchange
- MNPR Nasdaq
- KNOP Nasdaq
- Market Cap
- MNPR 244.1M
- KNOP 199.5M
- IPO Year
- MNPR 2019
- KNOP 2013
- Fundamental
- Price
- MNPR $40.33
- KNOP $6.67
- Analyst Decision
- MNPR Strong Buy
- KNOP
- Analyst Count
- MNPR 5
- KNOP 0
- Target Price
- MNPR $49.60
- KNOP N/A
- AVG Volume (30 Days)
- MNPR 30.6K
- KNOP 68.9K
- Earning Date
- MNPR 05-08-2025
- KNOP 03-19-2025
- Dividend Yield
- MNPR N/A
- KNOP 1.57%
- EPS Growth
- MNPR N/A
- KNOP N/A
- EPS
- MNPR N/A
- KNOP 0.40
- Revenue
- MNPR N/A
- KNOP $312,629,000.00
- Revenue This Year
- MNPR $34.06
- KNOP $1.40
- Revenue Next Year
- MNPR N/A
- KNOP $2.53
- P/E Ratio
- MNPR N/A
- KNOP $16.84
- Revenue Growth
- MNPR N/A
- KNOP 8.60
- 52 Week Low
- MNPR $1.72
- KNOP $4.94
- 52 Week High
- MNPR $54.30
- KNOP $9.11
- Technical
- Relative Strength Index (RSI)
- MNPR 56.65
- KNOP 71.40
- Support Level
- MNPR $36.80
- KNOP $5.35
- Resistance Level
- MNPR $43.00
- KNOP $6.84
- Average True Range (ATR)
- MNPR 5.32
- KNOP 0.22
- MACD
- MNPR 0.94
- KNOP 0.13
- Stochastic Oscillator
- MNPR 63.41
- KNOP 88.59
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About KNOP KNOT Offshore Partners LP Common Units representing Limited Partner Interests
KNOT Offshore Partners LP owns, operates, and shuttles tankers under long-term charters in the North Sea and Brazil. The company provides crude oil loading, transportation, and storage services under time charters and bareboat charters. The Partnership is formed for acquiring ownership interests in over four shuttle tankers owned by Knutsen NYK Offshore Tankers AS (KNOT). It operates through the shuttle tanker market segment.